Such monitoring is unsuccessful in 20–30% of melanoma cases that lack BRAF or NRAS mutations.1 Here we found significant correlation between CTC scores and ctDNA levels at baseline in treatment-naïve patients and observed comparable trends between CTC scores and ctDNA in patients with follow-up samples. Here, NRAS is linked to melanoma.